^
Association details:
| Biomarker: | RUNX1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) + cladribine (Purinergic receptor P1 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia
Published date:
03/26/2021
Excerpt:
High response rates and OS were observed in patients with mutations in NPM1, FLT3, IDH2, and RUNX1….The backbone of clofarabine or cladribine and LDAC alternating with decitabine was effective and safe for the treatment of older patients with newly diagnosed AML.
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.1002/ajh.26206
